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An imaging method capable of using a signal from pancreatic beta cells to determine their mass would be of immense value
in monitoring the progression of diabetes as well as response to treatment. Somatostatin receptors (SSTRs) are expressed on
beta cells and are a potential target for imaging. The main objective of this study was to investigate whether pancreatic beta
cells are a target for radiolabeled naphthylalanine derivatives. The molecules were subjected to in vitro and ex vivo evaluations.
Pancreatic uptake of radioactivity was lower in nonobese diabetic (NOD) mice than normal mice at all time points investigated
(P < .05) and correlated with the number of islets in tissue sections of both control and NOD mice. Immunohistochemical and
confocal ﬂuorescent microscopic studies showed colocalization of insulin and the conjugate radioligand in the pancreas. The
results demonstrated that pancreatic uptake is receptor-mediated, and that beta cells are the primary target.
Copyright © 2008 John K. Amartey et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Beta cell mass (BCM) in the pancreas is a key factor in
determining the amount of insulin secreted to maintain
normal blood glucose level. Currently, this information can
only be determined precisely at autopsy. Although BCM
can be deduced from blood measurements, it has not been
showntocorrelatewellwiththedysfunctionofbetacellsthat
result from morphological and biochemical changes in the
pancreas [1]. Additionally, there are no known noninvasive
methods to diﬀerentiate between functional and anatomical
defects in insulin secretion.
Insulin-dependent diabetes mellitus (type-1, T1D) is
characterized by an autoimmune process that leads to the
destruction of beta cells in individuals who are genetically
predisposed to the disease [2–5]. The occult phase of the
disease involves inﬁltration of the pancreas by mononuclear
cells that begins long before the onset of the disease
and progressively decreases as the BCM declines [6–12].
Consequently, after substantial loss of BCM and function,
there is a need for therapeutic insulin replacement (the overt
symptomatic phase of diabetes). One of the characteristics
of type 2 diabetes (T2D) is insulin resistance in a setting
of inadequate compensatory insulin secretory response.
Additionally,severalinsulinproductionandsecretionabnor-
malities have been described in patients with T2D [13].
Current treatment approaches for T2D include alterations in
diet, commencement of an exercise program, and a variety
of drugs such as insulin, biguanides, sulphonylureas (SUs),
and thiazolidinediones [6]. The success of any interventional
strategy may depend largely on a clear understanding of
diseaseprogression.Thelackofatechniquethatcanmeasure
or visualize pancreatic beta cells noninvasively has left
many unanswered questions regarding disease progression.2 Experimental Diabetes Research
Progress has been made towards imaging the endocrine
pancreas, and nuclear imaging leads the way relative to other
imaging modalities such as magnetic resonance imaging
(MRI) and optical imaging [11]. Indium-111-oxine-labeled
autologous lymphocytes [12], interleukin-2 labeled with
iodine-123 and technetium-99m [14–16], technetium-99m-
labeled human polyclonal immunoglobulins (Tc-99m-HIG)
[17], and a speciﬁc antibody to the islet antigen have been
reported as potential endocrine pancreas imaging agents
[18].
Modulation of insulin secretion by antidiabetic sec-
retagogues involves binding to high aﬃnity sulphony-
lurea receptors (SURs) expressed by beta cells. Hence,
SU analogs have been radiolabeled with ﬂuorine-18 and
carbon-11 and investigated as potential nuclear imaging
agents. The results from these studies were not satisfactory
because of negligible pancreatic uptake of the potential
tracers [19–21]. Clark et al. imaged the pancreatic body
with ﬂuorine-18-benzyltrozamicol [22]. This radioligand
binds speciﬁcally to neuroreceptors present on presynaptic
vesicles in neurons innervating the pancreas. Simpson et
al. recently reported imaging pancreatic beta cells using
[11C]dihydrotetrabenazine ([11C]-DTBZ), a ligand that tar-
gets the vesicular monoamine transporter expressed on
pancreatic beta cells in rodent models and in baboons [23–
25]. This is a promising radiotracer and was the ﬁrst of
the kind to be evaluated in primates as far as we know.
However, there are other potential targets that needed to be
investigated targeting the beta cells.
Somatostatin receptors (SSTRs) are expressed in the
endocrine pancreas, and ﬁve subtypes of human SSTRs
(hSSTR1–hSSTR5) have been cloned and characterized.
These receptor subtypes bind endogenous SST-14 and SST-
28 with low nanomolar aﬃnity. Reports on the selectivity
of all ﬁve subtypes for synthetic SST analogs have been
controversial [26–29]. However, of the known receptor
subtypes, SSTR1 and SSTR5 have been colocalized to these
cells [30–35]. Although there is no direct evidence of
association between BCM, aging, and the status of SSTRs
in diabetes, it is likely that destruction or decline in beta
cell numbers would result in reduction of the densities of
these receptors. We recently observed that a radioiodinated
derivative of naphthylalanine, (2R)-N-(6-amino-2,2,4-tri-
methylhexyl)-2-[(5-iodo(3-pyridyl))carbonylamino]-3-(2-
naphthyl)propanamide (IPC-β-AL3) localized to the pan-
c r e a si nm i c e[ 36]. In addition, we have synthesized (2R)-
-N-(6-amino-2,2,4-trimethylhexyl)-2-[(5-iodo(3-pyridyl))-
carbonylamino]-3-(naphthyl)propanamide, (IPC-α-AL3).
This paper reports further biological evaluation of the tra-
cers as potential pancreatic beta cell detection agents.
2. MATERIALS AND METHODS
All chemicals and reagents were purchased from Sigma-
Aldrich, Fisher, or Fluka. Radioactive samples were counted
in a Packard-Canberra Cobra 5000 gamma counter. The
NOD mice were purchased from Taconic, USA. Blood
glucose levels were measured with a glucometer (AccuCheck,
Roche).RadioligandbindingdatawasanalyzedusingGraph-
Pad Prism 4.0 (San Diego, USA).
2.1. Isolationofmousepancreaticislets
The method used was adopted from a published procedure
with minor modiﬁcations [37]. Brieﬂy, the pancreata of the
mice (females, aged 8weeks) were removed immediately
after death by CO2 asphyxiation and minced on ice in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM). Excess fat
was dissected and removed by washing with the medium.
The tissue was digested with collagenase type IV (10mg/g of
wet tissue) for 45minutes at 37◦Co nas h a k e r .T h er e a c t i o n
was quenched by the addition of DMEM supplemented
with 10% fetal bovine serum and centrifuged at 2000rpm
for 5minutes. The cell pellet was washed three times and
resuspended in the same medium containing 11mmol/L
glucose. Viability was checked by the trypan blue exclusion
method, and cells were quantiﬁed using a hemocytometer.
The islets were maintained in culture in the DMEM medium
at 37◦C and 5% CO2 atmosphere.
2.2. StabletransfectionofCHOcellswithsomatostatin
receptorsubtype-1(SSTR1)
The CHO cell line was obtained from ATCC (Rockville, MD,
USA) and maintained in Ham’s F12 medium supplemented
with fetal calf serum (10%), 100U/mL penicillin and
100μg/mL streptomycin in a humidiﬁed atmosphere con-
taining 5% CO2. The cells were transfected with the SSTR1
construct under the control of the CMV promoter (UMR
cDNA Resource Center, Rolla, MO, USA, www.cdna.org),
usinglipofectamine2000(Invitrogen,CA,USA).Forty-eight
hours after transfection, the cells were cultured in the F12
medium containing 400μg/mL of G418. Three weeks after
G418 selection, the stable clones were pooled for the binding
experiments.
2.3. Radioligandbindingstudies
The mouse islets were isolated as described above and used
immediately after recovery in DMEM medium containing
glucose (3mmol/L) for 60minutes. The [125I]-Tyr11-SS-14
was prepared as described earlier [36]. Brieﬂy, the islets were
placed in the binding buﬀer system (TRIS buﬀer 0.15 mol/L,
0.1% BSA, 1mmol/L CaCl2, 5mmol/L MgCl2,5 0 μg/mL
bacitracin, and 50μg phenylmethylsulfonylﬂuoride [PMSF])
inthepresenceofincreasingconcentrationoftheradioligand
(0.02–5nmol/L). The reactants were incubated for 1hour,
and the reaction was quenched with ice-cold buﬀer (1mL).
The cells were isolated using a cell harvester (Brandel, Inc.
USA) and washed twice with cold-buﬀered saline. Cell-
boundradioactivitywasassayedusingagammacounter.The
data were ﬁtted to a regression function to estimate binding
aﬃnity as well as receptor density. This data was published
previously [36]. The experiment was repeated using CHO
cell lines separately expressing SSTR1 and SSTR2 (SSTR2
was donated by Dr. Hans-J Wester, Technical University of
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two cell lines using increasing concentrations of SS-14, IPC-
α-AL3, and IPC-β-AL3 (10pmol/L–20μmol/L) and a ﬁxed
amount of [125I]-Tyr11-SS-14 (100,000cpm).
2.4. Biodistributionof[131I]-AL3derivativesinnormal
CBA/JandNODmice
The animal experiments were carried out in accordance
with institutional, national, and international guidelines
for humane use of animals in research, and the local
review committee approved the protocol. Each mouse (the
characteristics of the mice used are shown in Table 1)
was injected with 0.1mL of the [131I]-IPC-β-AL3 solution
containing 185kBq (5μCi) and approximately 500ng of the
labeled material. The mice were mildly anesthetized and
killed by cervical dislocation at 15, 30, 60, and 120minutes
post-injection. Organs and tissues of interest were dissected,
weighed, and counted in a gamma counter, calibrated for the
radionuclide.Thepercent-injectedactivitypergramoftissue
(per whole organ for the thyroid) was then calculated for
the samples. The injected activity per mouse was estimated
by counting a standard sample taken from the injectate.
The experiment was repeated in 16-week-old mice. Parallel
experiments were performed using NOD mice at 5, 8, and
16weeks old. The [131I]-IPC-α-AL3 was similarly tested in
5-week-old CBA/J mice.
2.5. Autoradiography
In the ex vivo experiment, two control CBA/J mice and
two NOD mice (17weeks old, blood glucose >300mg/dL)
were each injected with 740kBq (20μC i )o f[ 125I]-IPC-
β-AL3.The animals were killed 60minutes post injection.
Pancreata were harvested and washed in 50% aqueous
ethanol. The specimens were mounted on microscope slides,
carefully pressed so that they were spread out evenly, and
covered with a transparent adhesive tape. The samples
were imaged (InstantImager, Packard) for approximately
10minutes acquisition time. The experiment was repeated
ontwo26-week-oldNODmice(bloodglucose>400mg/dL),
where the animals were injected with the same amount of
radioactive tracer.
In a parallel experiment, ex vivo autoradiography was
performed in NOD and CBA/J mice, these animals were
17weeks old. The animals were killed, and pancreata were
removed and ﬁxed in PBS-formalin (4%, pH 7.5). The
samples were processed and embedded in paraﬃn. Sections
(5μm) were deparaﬃnized in xylene and rehydrated in
graded ethanol (100%, 95%, 75%) to deionized water. The
mounted sections were incubated with the radioiodinated
IPC-β-AL3 (500,000cpm) for 60minutes at ambient tem-
perature. The slides were washed thoroughly with binding
buﬀer, and the samples imaged.
2.6. Microscopy/immunohistochemistry
To investigate the cellular location of the radiolabeled tracer
observed in the biodistribution and ex vivo autoradio-
graphic studies, immunoﬂuorescence and histology exper-
iments were performed. Fluorescein isothiocyanate-labeled
β-AL3 (β-AL3-FITC) was prepared by incubating equimolar
amounts (6μmol) of β-AL3 and FITC in methanol in
the presence of triethylamine at ambient temperature for
60minutes. The solid product was isolated and charac-
terized by electrospray mass spectroscopy. Normal CBA/J
and NOD mice (16weeks old) were injected with β-AL3
(β-AL3-FITC, 1μg/mouse). One hour post administration,
the animals were killed and pancreata were removed and
ﬁxed in PBS-formalin (4%, pH 7.5). The samples were
embedded in paraﬃn, and thin sections (5μm) were cut
and stained with hematoxylin and eosin. For colocalization
experiments, comparable sections were deparaﬃnized in
xylene and rehydrated in graded ethanol (100%, 95%, 75%)
to deionized water, permeabilized with Triton X100 and
treated with both β-AL3-FITC (1μg/mL) and anti-insulin
antibody (mouse monoclonal IgG, Santa Cruz Biotechnol-
ogy, USA) for 60minutes at ambient temperature. They
were then viewed by confocal microscopy (images were
acquired using UltraView LCI confocal system (PerkinElmer,
USA). Images were processed using Volocity improvision
software (Improvision Inc. Coventry, UK) using indirect
immunoﬂuorescence of TRITC-conjugated aﬃnity puriﬁed
donkeyantimouseIgG(JacksonImmunoResearchLabs,Inc.,
USA). These colocalization experiments were conﬁrmed
using isolated formalin-ﬁxed mouse islets. The islets were
isolated as described earlier. To test whether the uptake of
β-AL3-FITC by the islets and ﬁxed sections was mediated
through AL3, the experiment was repeated with ﬂuorescein
isothiocyanate alone.
2.7. Statisticalanalysis
Meanswerecomparedusingstudent’s t-test,andaP-valueof
< 0.05 was considered signiﬁcant.
3. RESULTS
3.1. Radioligandbindingstudies
Radioligand binding studies were performed to assess the
integrity of the isolated islets. [125I]-Tyr-SS-14 was used
in saturation as well as displacement studies. The receptor
binding studies performed with SSTR1 cells revealed that a
bindingequilibriumwasattainedafter60minutesatambient
temperature. The estimated βmax was 1 × 103 receptors/cell.
The IC50 values for IPC-β-AL3 for the SSTR1 and SSTR2
expressing cell lines were 1.83nM and 297nM, respectively
(see Figure 1). IPC-α-AL3 was of low aﬃnity and was in the
μM range (data not shown).
3.2. Biodistributionandautoradiography
The initial biodistribution was performed in sex- and age-
matched nonobese diabetic (NOD) and normal CBA/J mice.
A statistically signiﬁcant diﬀerence in the pancreatic uptake
of radioactivity was observed at 5weeks of age. When the
experiment was repeated on 8- and 16-week-old NOD and
theCBA/Jmice,pancreaticuptakeagainshowedasigniﬁcant4 Experimental Diabetes Research
Table 1:Characteristicsofmiceusedinthebiodistributionstudies.Valuesaremeans ±standarddeviationsforn ≥ 4.ND =notdetermined.
Age (weeks) CBA/J NOD
Weight (g) Glucose (mg/dL) Weight (g) Glucose (mg/dL)
52 2 ± 3 70–100 22 ± 3 88–160
8N D N D 2 5 ± 2 120–180
16 27 ± 3 70–90 26 ± 2 260–450
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Figure 1: Competitive radioligand binding plots, using [125I]-
Tyr11-SS-14 as the radioligand on the two cell lines demonstrated
higher aﬃnity for SSTR1 than SSTR2. (Data for IPC-a-AL3 were
not included because of low speciﬁcity.)
diﬀerence between the two groups (P<. 05). Although the
uptake in the 8-week-old NOD mice was slightly higher than
that of the 16-week-old NOD mice, the diﬀerence was not
statistically signiﬁcant (P<. 05). Figure 2 shows the general
biodistribution of the tracer in NOD mice at 5 weeks of age.
Uptake decreased with age in the NOD mice (see Table 2),
but not in the CBA/J mice.
Autoradiographswere obtained by imaging the pancreata
of the CBA/J and NOD mice. The images demonstrated
that at 16weeks old, there was a signiﬁcant diﬀerence in
pancreatic uptake between the mouse strains (see Figures
3(a)–3(d)). Figure 3(e) shows the image for a 26-week-old
NOD mouse. According to ex vivo autoradiograms (see
Figures 3(f)–3(h)), the extent of radioactivity accumulation
correlated with the number of visible islets in pancreatic
sections of the CBA-J mouse under light microscope (see
Figure 4(e)).
3.3. Microscopy/immunohistochemistry
To further corroborate this autoradiographic observation
and the results of the radiotracer biodistribution studies,
the colocalization experiment was repeated on islets isolated
from normal CBA/J mice. This experiment could not be
repeated in the NOD mice because enough islets could not
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Figure 2: Biodistribution of [131I]-IPC-β-AL3 in NOD mice.
The values are means and standard deviations of % injected
radioactivity per gram. Each point represents n ≥ 4 mice at 5weeks
old.
be obtained. Additionally, hematoxylin-eosin stained and
unstained sections showed no visible islets in 26-week-old
NOD mice. However, there were islets of varying dimensions
in the normal mice (see Figures 4(a)–4(e)). Fluorescence
microscopy and histology experiments showed that the
conjugate localized to the cell membrane (see Figure 5(a)).
When ﬂuorescein isothiocyanate alone was used, the uptake
of dye in the pancreas was largely nonspeciﬁc. This indicated
that the localization process was mediated through the
AL3 portion of the conjugate. Confocal laser scanning
microscopyrevealedcolocalizationoftheligandwithinsulin.
The insulin was localized to the cell membrane as well as
in the cytoplasm, whereas the tracer was apparently cell
membrane-bound (see Figure 5(b)).
4. DISCUSSION
Although progress has been reported in recent years [18, 22–
25],suchanimagingmodality hasnotyetbeenfullyrealized.
We recently reported the synthesis of a radiolabeled pep-
tidomimetic based on (D)-2-naphthylalanine and hexanedi-
amine and performed initial in vitro and in vivo evaluations.
Our results indicated that the tracer was localized in the
normal mouse pancreas [36]. We have further evaluated theJohn K. Amartey et al. 5
Table 2: Comparative biodistribution of [131I]-IPC-β-AL3 in normal CBA/J and NOD mice with age, 60minutes post injection. Values are
means ± standard deviations of % ID/g, where n ≥ 4 per time point. The small intestine was measured with its contents. The value for the
thyroid is for the whole organ (% ID/organ).
Mouse groups by age (weeks) and strain
58 1 6
Organ/Tissue CBA/J NOD CBA/J NOD CBA/J NOD
Blood 0.7 ±0.11 .2 ±0.10 .9 ±0.20 .6 ±0.10 .5 ±0.10 .3 ±0.1
Heart 1.8 ±0.60 .7 ±0.22 .3 ±0.71 .0 ±0.41 .2 ±0.20 .5 ±0.1
Intestine (small) 20.7 ±13.31 0 .5 ±2.77 .4 ±1.9∗ 3.3 ±1.5∗ 12.5 ±3.91 7 .1 ±5.1
Kidney 24.6 ±7.96 .5 ±0.61 3 .2 ±3.36 .5 ±1.61 4 .4 ±4.35 .3 ±1.1
Liver 3.9 ±0.63 .3 ±0.84 .4 ±0.43 .6 ±1.42 .7 ±0.62 .1 ±0.4
Lung 5.8 ±1.62 .3 ±0.33 .6 ±1.02 .3 ±1.03 .4 ±0.73 .8 ±1.6
Muscle — 0.4 ±0.10 .5 ±0.10 .3 ±0.1—0 .3 ±0.1
Pancreas 5.5 ±1.12 .3 ±0.23 .4 ±1.31 .9 ±0.85 .2 ±0.61 .6 ±0.3
Spleen 5.2 ±1.11 .7 ±0.52 .8 ±1.11 .8 ±0.84 .4 ±2.11 .1 ±0.3
Thyroid 0.4 ±0.2— — — 0 .2 ±0.1— -
∗ The intestines were measured without their contents.
(a) (b) (c) (d)
(e) (f) (g) (h)
Figure 3: Autoradiographic images of mice pancreas injected with [125I]-IPC-β-AL3 and sacriﬁced 60minutes post injection. (a) and (b) =
CBA/J normal mice, (c) and (d) = 17-week-old, and (e) = 26-week-old NOD mice injected with the same quantity of radioactivity. Note the
intense and scattered radioactivity in the CBA/J mice. Ex vivo autoradiograms of pancreata from normal (CBA/J) and diabetic (NOD) mice
(17weeks old). The sections were 5μm in thickness, and images were from 30minutes of exposure. (f) and (g) = CBA/J, (h) = NOD.
radiotracersandshownthatthepancreaticbetacellswerethe
main target.
4.1. Radioligandbindingstudies
Radioligand binding studies performed on isolated mouse
islets and two Chinese hamster ovary (CHO) cell lines
separately expressing SSTR1 and SSTR2 yielded Kd and IC50
values that were consistent with previously reported values
[38]. Likewise, evaluation of SSTR1 expression in SSTR1-
transfected cells using a radiolabeled SST analog revealed
that the SST analog aﬃnity was in the nanomolar range, and
that the number of receptors per cell was in the 103 range.
The results showed that the selectivity of the radioligand for
SSTR1 was greater than 100 times in comparison with the
SSTR2.6 Experimental Diabetes Research
(a) (b) (c)
(d) (e)
Figure 4: (a) Light and ﬂuorescent micrographs of an islet, (b) the same islet labeled with AL3-FITC, (c) and the two images superimposed.
(d) A hematoxylin and eosin stained section from an NOD mouse (e) and normal CBA/J pancreatic sections (e; 10× magniﬁcation). Note
the presence of islets in the normal pancreas (arrows) and none in the diabetic.
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Figure 5: (a) A representative tomographic image of an islet stained with AL3-FITC. Note the concentration of the compound in the cell
membrane. (b) Confocal laser scanning ﬂuorescent micrographs of isolated mouse islet indirectly labeled for insulin (red) and AL3-FITC
(green). The superimposed images are shown in the lower right micrograph.
4.2. Biodistributioninmice
A statistically signiﬁcant diﬀerence (P<. 05) in the
pancreatic uptake of radioactivity was observed at 5weeks
of age. This experiment was repeated when the mice were
8 and 16weeks old, and pancreatic uptake again showed
a signiﬁcant diﬀerence between the CBA/J and NOD age
groups. This observation may be indicative of the severity of
diabetes in these mice. The biodistribution data also showed
that the decrease in pancreatic uptake was not age related.
We did not observe any signiﬁcant diﬀerence in the control
mice between 5 to 16weeks of age. However, as a potential
imaging agent for the beta cells the relatively higher uptake
in the liver, intestine, and the spleen is a major drawback
because of the proximity of these organs to the pancreas.
This potential interference may be minimized by making theJohn K. Amartey et al. 7
tracerlesslipophilic.Oneapproachwillbetoprepareametal
(Tc-99m) chelate by attaching a chelator to the nonessential
part of the molecule.
4.3. Autoradiography
Radioactivity was localized and concentrated in the pancreas
in a pattern similar to the anatomical structure of islets
in the pancreas. Our observations reﬂected the typical
scattered appearance of islets in the pancreas surrounded by
nonendocrine tissue [18]. Although we did not quantify the
beta cells in the islets in the ﬁxed pancreatic sections, visual
counting under a light microscope showed that there were
several islets of varying sizes. This observation correlated
with the extent of radioactivity accumulation in the ex vivo
autoradiograms.
4.4. Histologyandmicroscopicstudies
The heterogeneous distribution pattern of radioactivity
within the pancreas seemed to follow the variation of islet
sizes and densities seen in the hematoxylin-eosin stained
sections. However, the NOD mice showed pancreatic uptake
slightly above background radioactivity. This observation
may be due to nonspeciﬁc binding and conﬁrmed what
we observed in the previous blocking studies [36]. The
uptake was increased 2-3 folds in the normal compared with
the NOD mice at 26weeks of age. The lack of substantial
radioactivity in the pancreata of NOD mice was conﬁrmed
by the paucity of visible islets in the pancreatic sections of
these mice. Nonetheless, the apparent high uptake in the
CBA/J mice cannot be explained by perfusion alone since
the circulating radioactivity in the blood was low at later
time points in the biodistribution experiments. Additionally,
if the uptake in the pancreas wasdue to inﬂammation during
immune cell inﬁltration of the pancreas (associated with
leaky vasculature), then the NOD mice would be expected
to show a higher uptake than normal CBA/J mice, but this
was not observed.
Fluorescence microscopy and histology experiments
indicated that the localization process was mediated through
the AL3 portion of the conjugate. The insulin was localized
to the cell membrane as well as in the cytoplasm; whereas
the tracer was apparently cell membrane-bound. There are
two possible explanations for this result. It may be due
to the presence of insulin bound to its receptors on the
plasma membranes of the islets, or due to leakage of insulin,
which was then ﬁxed to the plasma membrane during tissue
processing, from the secretory granules. Nonetheless, these
data suggest that the tracer localizes to the islets, and the
beta cells are its target. Consistent with our prior result,
when the colocalization experiment was repeated on isolated
mouse islets, images of live cells demonstrated that insulin
was present in the cell membrane as well as in the cytoplasm,
while the tracer was bound to the cell membrane. These
radioligand binding and live cell imaging data indicate that
the uptake of radioactivity in the pancreas was receptor-
mediated and that SSTR1, but not SSTR2, was largely
targeted.
Collectively, the data show that the tracer binds to
beta cells. The extent of localization may be indicative of
the stage of diabetes development in these mice. Although
the results showed a reasonable contrast between normal
and diabetic pancreata, in our estimation, it was not high
enough for good in vivo imaging. The data also suggest
SSTR1 involvement in the pancreatic uptake of the tracer;
however, there appeared to be nonspeciﬁc binding as well.
To overcome this shortcoming, this molecule may need to be
optimized to obtain a higher signal-to-background ratio by
decreasing the lipophilicity. This investigation is already in
progress in our laboratory.
5. CONCLUSION
Our results indicate that this novel radiotracer targets beta
cells in the mouse pancreas. We can also infer that decreased
pancreatic uptake of the radiotracer in NOD mice may be
directly related to the progressive destruction of beta cells in
these mice.
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